Cuproptosis‑related Gene CDKN2D is Linked to Prognosis in Esophageal Cancer-Scilight

ENT Updates

Original Article

Cuproptosis‑related Gene CDKN2D is Linked to Prognosis in Esophageal Cancer

Downloads

https://doi.org/10.54963/entu.v15i3.1367
Xu, X., Ma , L., & Liu, S. (2025). Cuproptosis‑related Gene CDKN2D is Linked to Prognosis in Esophageal Cancer. ENT Updates, 15(3), 27–41. https://doi.org/10.54963/entu.v15i3.1367
Volume 15 Issue 3 (2025): In Progress
Copyright (c) 2025 Xingnong Xu, Lei Ma , Shichao Liu
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors

  • Xingnong Xu

    1. School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
    2. Department of Pharmacy, Yancheng Third People’s Hospital, Yancheng 224000, China
  • Lei Ma

    School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
  • Shichao Liu

    College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China

Cuproptosis, a novel type of regulated cell death, is controlled through protein fatty acylation and has been linked to mitochondrial metabolic processes. Nonetheless, continued research efforts are essential to determine how CDKN2D (Cyclin-dependent kinase inhibitor 2D), a gene associated with cuproptosis, influences the tumor immune microenvironment and progression of esophageal cancer (EC). Gene expression levels of CDKN2D in EC and matched normal tissues were assessed using data from The Cancer Genome Atlas (TCGA). To confirm these findings, we conducted validation analyses utilizing datasets from the Gene Expression Omnibus (GEO) and the Human Protein Atlas (HPA). To ascertain if CDKN2D expression levels were associated with clinical outcomes, we conducted a multivariable regression analysis supplemented by Kaplan-Meier survival estimates. The protein-protein interaction network related to CDKN2D was created using the STRING database (Search Tool for the Retrieval of Interacting Genes/Proteins). To characterize the immunological relevance of CDKN2D in EC, we performed comprehensive bioinformatic analyses to assess its correlation with tumor-infiltrating immune cells. Three complementary computational approaches-Gene Ontology (GO) functional annotation, conventional GSEA, and ssGSEA (single-sample GSEA) were integrated to evaluate the immunomodulatory potential of CDKN2D in EC. Transcript abundance level of the CDKN2D in EC samples is considerably higher than in normal tissue samples. Analyses involving both single variables and multiple variables indicate that there is no significant statistical difference in overall survival (OS) between EC patients with high CDKN2D expression and those with low CDKN2D expression (p > 0.05). Cyclin-dependent kinase 4/6 (CDK4/6) is a critical protein that interacts with the CDKN2D gene, and ECs with high CDKN2D expression are bound to a considerable volume of infiltrating immunocytes. Elevated CDKN2D expression in EC correlated with disease progression and modified immune infiltration patterns.

Keywords:

CDKN2D Esophageal Cancer Immune Cells CDK4/6

References

  1. Lingling, L.; Dongxian, J.; Qiao, Z.; et al. Integrative proteogenomic characterization of early esophageal cancer. Nat. Commun. 2023, 14, 1666.
  2. Xiaofeng, C.; Xiang, X.; Danping, W.; et al. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): An open-label, single-arm, phase 2 trial. J. Immunother. Cancer 2023, 11, e005830.
  3. Lei, C.; Wenjing, Z.; Dan, C.; et al. RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis. Signal Transduct. Target Ther. 2023, 8, 159.
  4. Xu, Z.; Yuxiang, W.; Xi, Z.; et al. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors. Signal Transduct. Target Ther. 2023, 8, 153.
  5. Qing, W.; Wei, Q.; Xiaoli, S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J. Hematol. Oncol. 2022, 15, 143.
  6. Paridisha, D.; Rajkumar, D.; Elisha, T.S.; et al. Esophageal cancer in Northeast India: A comprehensive review of risk factors, diagnosis, and therapeutic approaches. J. North East Counc. 2024, 25, 38–53.
  7. Alei, F.; Ning, Y.; Ruoying, Y.; et al. Prognostic implications of six altered genes in Asian non-surgical esophageal carcinoma patients treated with chemoradiotherapy. Onco Targets Ther. 2022, 15, 41–51.
  8. Hana, Q.S.; Alanoud, A.; Sara, A.M.; et al. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Transl. Oncol. 2024, 39, 101821.
  9. Bujiang, W.; Haojun, S.; Haizhong, J.; et al. Early diagnostic potential of APC hypermethylation in esophageal cancer. Cancer Manag. Res. 2018, 10, 181–198.
  10. Yong, X.; Yaxing, S.; Donglei, W.; et al. CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p. Mol. Cancer 2022, 21, 145.
  11. Liyun, C.; Junxia, M.; Fudi, W. Copper homeostasis and cuproptosis in health and disease. Signal Transduct. Target Ther. 2022, 7, 378.
  12. Paul, A.C.; Donita, C.B. Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death. Mol. Cell 2022, 82, 1786–1787.
  13. Hongyan, Z.; Yujie, G.; Yong, W.; et al. LncRNA CRNDE promotes the progression and angiogenesis of pancreatic cancer via miR-451a/CDKN2D axis. Transl. Oncol. 2021, 14, 101088.
  14. Keyi, Z.; Xiao, N.; Xiaoling, M.; et al. LINC01012 upregulation promotes cervical cancer proliferation and migration via downregulation of CDKN2D. Oncol. Lett. 2023, 25, 124.
  15. Wioletta, R.K.; Radosław, W.; Jacek, P.S.; et al. The genetic and endoplasmic reticulum-mediated molecular mechanisms of primary open-angle glaucoma. Int. J. Mol. Sci. 2020, 21, 4171.
  16. Aimin, J.; Peng, L.; Ming, C.; et al. A new thinking: Deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. Cell Biosci. 2022, 12, 209.
  17. Shuai, Z.; Shuxian, C.; Wangrui, L.; et al. Integrated machine learning and bioinformatic analyses used to construct a copper-induced cell death-related classifier for prognosis and immunotherapeutic response of hepatocellular carcinoma patients. Front. Pharmacol. 2023, 14, 1188725.
  18. Kuanhao, T.; Juihu, H.; Lite, L.; et al. The cross-communication of cuproptosis and regulated cell death in human pathophysiology. Int. J. Biol. Sci. 2024, 20, 218–230.
  19. Tao, W.; Yufeng, L.; Qing, L.; et al. Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma. Front. Immunol. 2022, 13, 999823.
  20. Nathaniel, D.; Christopher, M.J.; Kohei, Y.; et al. Advances in diagnosis and management of cancer of the esophagus. BMJ 2024, 385, e074962.
  21. Hong, Y.; Feng, W.; Christopher, L.H.; et al. Oesophageal cancer. Lancet 2024, 404, 1991–2005.
  22. Meilin, L.; Yu, T.; Zhixin, L.; et al. Biological characterization and clinical significance of cuproptosis-related genes in lung adenocarcinoma. BMC Pulm. Med. 2025, 25, 13.
  23. Chenglin, L.; Ying, L.; Nasra, M.A.; et al. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front. Immunol. 2023, 13, 1039260.
  24. Baowen, X.; Kaiyong, Y.; Xin, H.; et al. Cuproptosis-related gene CDKN2A as a molecular target for IPF diagnosis and therapeutics. Inflamm. Res. 2023, 72, 1147–1160.
  25. Vinicio, M.; Edwin, B.; John, D.M. Towards immunotherapy-induced normalization of the tumor microenvironment. Front. Cell Dev. Biol. 2022, 10, 908389.
  26. Ziheng, Z.; Yajun, H.; Yuefeng, C.; et al. Immunometabolism in the tumor microenvironment and its related research progress. Front. Oncol. 2022, 12, 1024789.
  27. Bo, H.; Xiaobo, Y.; Xinting, S. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma. Cancer Med. 2020, 9, 7646–7662.
  28. Li, M.; Xian, H.C.; Tang, Y.J.; et al. Fatty acid oxidation: Driver of lymph node metastasis. Cancer Cell Int. 2021, 21, 339.
  29. Henggang, W.; Cheng, W.; Yajun, L.; et al. miR-138-5p suppresses glioblastoma cell viability and leads to cell cycle arrest by targeting cyclin D3. Oncol. Lett. 2020, 20, 264.
  30. Dorian, V.Z.; Kanishka, P.; Lluis, F. Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer. Semin. Cancer Biol. 2024, 98, 51–63.
  31. Sofie, N.; Karoline, K.; Veronika, S. The role of CDK6 in cancer. Int. J. Cancer 2020, 147, 2988–2995.
  32. Jomrich, G.; Paireder, M.; Gleiss, A.; et al. Comparison of inflammation-based prognostic scores in a cohort of patients with resectable esophageal cancer. Gastroenterol. Res. Pract. 2017, 12, 1678584.
  33. Xiaofeng, Y.; Jun, C.; Dingsen, S.; et al. Advanced esophageal cancer with bone metastases: Prognostic biomarkers and palliative treatment. Heliyon 2024, 10, e23510.
  34. Junjie, L.; Shuoyi, M.; Yantao, Z.; et al. Prognostic value and immune infiltration analyses of cuproptosis-related genes in hepatocellular carcinoma. Acta Mater. Med. 2023, 2, 386–399.
  35. Dongmei, L.; Songyang, L.; Jie, L.; et al. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia. Clin. Transl. Oncol. 2023, 25, 2393–2407.
  36. Xiangxu, W.; Shizhou, D.; Lihong, W.; et al. Cuproptosis-mediated patterns characterized by distinct tumor microenvironment and predicted the immunotherapy response for gastric cancer. ACS Omega 2023, 8, 10851–10862.
  37. Sahar, Y.; Monireh, M.; Somayeh, Y.; et al. The mirror like expression of genes involved in the FOXO signaling pathway could be effective in the pathogenesis of human lymphotropic virus type 1 (HTLV-1) through disruption of the downstream pathways. BMC Res. Notes 2023, 16, 147.
  38. Hui, L.; Songhao, J.; Kun, G.; et al. INK4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma. Biosci. Rep. 2022, 42, 1082.
  39. Karam, K.; Lucas, M.; Anamaria, A.R.; et al. Melanoma targeted therapies beyond BRAF-mutant melanoma: Potential druggable mutations and novel treatment approaches. Cancers 2021, 13, 5847.